UK 453,061

Known as: UK453061, UK 453061, UK-453061 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2012
02420082012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
OBJECTIVE A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… (More)
Is this relevant?
2012
2012
AIMS To investigate the effect of inhibitors of cytochrome P450 (CYP) 3A4 and glucuronidation (UGT2B7) on the pharmacokinetics of… (More)
Is this relevant?
2012
2012
OBJECTIVE Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type… (More)
Is this relevant?
2012
2012
Lersivirine (UK-453,061) is a new nonnucleoside reverse transcriptase inhibitor currently being developed as a treatment for… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2010
2010
Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor that displays potent antiviral… (More)
  • figure 1
  • table 1
Is this relevant?
2010
2010
Lersivirine [UK-453,061, 5-((3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile] is a next… (More)
Is this relevant?
2009
2009
We prepared three discreet cohorts of potent non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) based on the recently… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
OBJECTIVE To investigate the effects on viral load and assess dose-response relationships, pharmacokinetics, safety and… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • table 3
Is this relevant?
2009
2009
The requirements for safe testing of pharmaceuticals in humans places substantial emphasis on the translation of safety testing… (More)
Is this relevant?
2008
2008
1. UK-453,061 is a novel second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Following intravenous bolus… (More)
Is this relevant?